(Reuters) - DUBLIN, April 24 - Drug-maker Elan Corp posted a wider-than-expected first-quarter loss on Tuesday after repaying debt but said it was on track to meet full-year goals thanks to a new multiple sclerosis treatment.
"The net loss increased, mainly due to a charge in respect of the early retirement of debt this quarter and the inclusion of a gain on the sale of EU rights to Prialt in 2006," Chief Financial Officer Shane Cooke said in a statement.
Read more at Reuters.com Market News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment